Accession Number:



Study of Immune-Based Biomarkers Using the Longitudinal CLIMB Dataset

Descriptive Note:

Technical Report,01 Sep 2018,31 Aug 2019

Corporate Author:

Brigham and Womens Hospital Boston United States

Personal Author(s):

Report Date:


Pagination or Media Count:



During this period, we have evaluated proteomic biomarkers and their associations with relapses andor new gadolinium enhancing lesions GD and 10-year outcomes in MS patients. We have specifically identified that serum neurofilament light chain sNFL is elevated within a 3-month window of new GD MRI lesions, which informs the frequency at which this biomarker may be surveyed in the clinical setting. We have also found that at a relapse or GD lesion that sNFL decreases with increasing age, with the opposite in remission samples. We have screened over 1100 other proteins and have identified a multivariate proteomic signature that more strongly associates with GD lesions than serum NFL alone. We have found that serum NFL levels within the first 3-5 years after disease onset strongly correlate with10-year brain atrophy and deep grey matter volumes including thalamic volumes. These findings can inform the uses of sNFL and a multivariate proteomic biomarkers in clinical MS settings.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: